Drug Trial Radar · NCT03770000
Safety and Efficacy of Tenalisib (RP6530) in Combination With Romidepsin in Patients With Relapsed/Refractory T-cell Lymphoma
Last checked: Nov 19, 2026Latest source record: Oct 28, 2022 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
33
Actual
Start
Mar 12, 2019
Primary completion
May 14, 2021
Study completion May 14, 2021
Sponsor
- Lead sponsor
- Rhizen Pharmaceuticals SAIndustry
- Sponsor type
- Industry
- First posted
- Dec 10, 2018
Design
- Study type
- Interventional
- Phase
- Phase 1 / Phase 2
- Allocation
- Not applicable (single group)
- Model
- Sequential
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
To characterize safety, tolerability and to establish the maximum tolerated dose (MTD) of Tenalisib in combination with Romidepsin in patients with R/R T-cell lymphoma.
Conditions
- T Cell Lymphoma
Interventions
TenalisibDrug
Tenalisib, BID orally daily
RomidepsinDrug
Romidepsin IV
Primary outcomes
What the sponsor says the trial is designed to measure.
- Number of Participants With and Without Dose Limiting Toxicities (DLTs)Time frame: 28 days
Locations
15 sites in 1 country. Site status is shown where the registry gives one.
USC/Norris Comprehensive Cancer Center
Los Angeles, California
University of California, Hellen Diller Family Comprehensive Cancer Center
San Francisco, California
University of Colorado Cancer Center
Aurora, Colorado
University of Miami-Sylvester Comprehensive Cancer Center
Miami, Florida
Winship Cancer Institute of Emory University
Atlanta, Georgia
Rush University Cancer Center
Chicago, Illinois
The University of Kansas Cancer Center
Fairway, Kansas
Norton Cancer Institute, St Matthews Campus
Louisville, Kentucky
University of Michigan
Ann Arbor, Michigan
John Theurer Cancer Center, Hackensack University Medical Center
Hackensack, New Jersey
Roswell Park Comprehensive Cancer Center
Buffalo, New York
Cleveland Clinic Taussig Cancer Institute
Cleveland, Ohio
Oregon Health & Science University
Portland, Oregon
Vanderbilt Ingram Cancer Center
Nashville, Tennessee
The University of Texas MD Anderson Cancer Center,
Houston, Texas
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.